Clinical Trial: Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07902726) titled 'Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes' on Oct. 20.

Brief Summary: The study aims to determine the acute efficacy and safety of three sequential doses of acetazolamide (62.5 mg, 125 mg, 250 mg) each for 2 weeks in 20 patients with T2D receiving background SGLT2i therapy.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: T2D

Intervention: DRUG: Acetazolamide 62.5 mg

Oral acetazolamide 62.5 mg twice daily for 2 weeks

DRUG: Acetazolamide 125 mg

Oral acetazolamide 125 mg twice daily for 2 weeks

DRUG: Acetazolamide 250 mg

Oral acetazolamide 250 mg twice daily for 2 weeks ...